GSK Reports Mixed Phase III Results for Camlipixant in Refractory Chronic Cough: CALM-1 Trial Meets Primary Endpoint While CALM-2 Falls Short
GlaxoSmithKline plc (GSK) (NYSE: GSK) announced mixed results from the CALM-1 and CALM-2 Phase III...
Wepon Medical Secures FDA Clinical Approval for WP107 (Huperzine A Oral Solution) in Healthy Volunteers Following NMPA Clearance for Myasthenia Gravis
Wepon Medical Holding Group Co., Ltd. (SHE: 002082) announced that WP107 (Huperzine A Oral Solution)...
Jacobio Launches Phase Ib/III Trial of Pan-KRAS Inhibitor JAB-23E73 for KRAS-Mutated Pancreatic Cancer in Partnership with AstraZeneca
Jacobio Pharmaceuticals Group Co., Ltd. (HKG: 1167) announced that the first patient has been dosed...
CSPC Pharmaceutical Launches Phase III Trial of B7-H3-Targeting ADC SYS 6043 for Platinum-Resistant Ovarian Cancer
CSPC Pharmaceutical Group (HKG: 1093) announced the initiation of a randomized, multi-center, open-label Phase III...
CSPC Pharmaceutical Launches Phase II Trial of Albumin-Bound Sirolimus for Rare Vascular Tumor Epithelioid Hemangioendothelioma
CSPC Pharmaceutical Group (HKG: 1093) announced the initiation of a Phase II clinical trial of...
Immvira Bioscience Files for Hong Kong IPO to Advance Novel Oncolytic Immunotherapy and Engineered Exosome Pipeline
Immvira Bioscience Inc., a clinical-stage biotechnology company founded in 2015, has filed its prospectus for...
Abbott Reports Strong Q2 2026 Results with 12.2% Revenue Growth Driven by Diagnostics Surge and Medical Device Innovation
Abbott Laboratories (NYSE: ABT) reported second-quarter 2026 financial results with total revenue of $12.593 billion,...
Hengrui’s HRS9531 Dual GIPR/GLP-1R Agonist Advances to Phase III for Obesity with Knee Osteoarthritis, Expanding Metabolic Disease Portfolio
Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276; HKG: 1276) announced that its HRS9531 injection has...
Sichuan Biokin’s Yizekang Receives NMPA Approval as World’s First EGFR×HER3 Bispecific ADC for Esophageal Squamous Cell Carcinoma
Sichuan Biokin Pharmaceutical Co., Ltd. (SHA: 688506) announced that China’s National Medical Products Administration (NMPA)...
Eli Lilly to Acquire AtaiBeckley for $3.8 Billion, Accelerating Psychedelic Therapeutics Development for Treatment-Resistant Depression
Eli Lilly and Company (NYSE: LLY) announced a definitive agreement to acquire AtaiBeckley (NASDAQ: ATAI),...
Novartis’ Fabhalta Receives FDA Approval as First Oral Complement Factor B Inhibitor to Slow Renal Decline in Primary IgA Nephropathy
Novartis AG (NYSE: NVS) announced that the U.S. Food and Drug Administration (FDA) has granted...
Shionogi’s Fetroja Receives FDA Acceptance for Pediatric sNDA Expanding Use to Gram-Negative Infections in Hospital-Acquired Pneumonia and Complicated UTIs
Shionogi & Co., Ltd. (TYO: 4507) announced that the U.S. Food and Drug Administration (FDA)...
Merck’s Lipfendra Receives FDA Approval as First Oral PCSK9 Inhibitor for LDL Cholesterol Reduction in Hypercholesterolemia Patients
Merck & Co., Inc. (MSD; NYSE: MRK) announced that the U.S. Food and Drug Administration...
Jasper Therapeutics Completes Acquisition of Kira Pharmaceuticals in All-Stock Transaction, Secures $132M Private Placement for Complement Therapies Pipeline
Jasper Therapeutics, Inc. (NASDAQ: JSPR) announced the completion of its acquisition of Kira Pharmaceuticals through...
DP Technology, Excalipoint Therapeutics Launch AI Antibody Discovery Platform Through Strategic Partnership Focused on T-Cell Engagers
DP Technology and Excalipoint Therapeutics announced a strategic partnership to co-develop a dedicated AI Antibody...
InnoCare Pharma’s Soficitinib Meets Primary Endpoint in Phase III Atopic Dermatitis Trial as Highly Selective TYK2 Inhibitor
InnoCare Pharma Limited (HKG: 9969, SHA: 688428) announced today that the Phase III registrational clinical...
Amoytop Biotech Secures NMPA Clinical Trial Approval for ACT201, Novel ASO Therapy for Chronic Hepatitis B
Amoytop Biotech (SHA: 688278) announced today that its investigational drug ACT201 has received clinical trial...
Boehringer Ingelheim Reports 16.2% H1 2026 Sales Growth Driven by JARDIANCE and New Oncology Launches
Boehringer Ingelheim reported continued strong sales growth in the first half of 2026 (H1 2026),...
China Resources Pharmaceutical to Acquire 23.5% Stake in Lier Chemical to Advance Synthetic Biology Pipeline
China Resources Pharmaceutical (HKG: 3320) announced today its plan to acquire 188,102,749 shares of Lier...
Harbour BioMed and Kelun-Biotech Secure NMPA IND Approval for HBM7575/SKB575, Long-Acting Bispecific Antibody for Asthma
Harbour BioMed (HKG: 2142) and Kelun-Biotech (HKG: 6990) announced today that the Investigational New Drug...